Skip to main content
Top
Published in: Hepatology International 3/2008

Open Access 01-09-2008 | Original Article

Demographics of a large cohort of urban chronic hepatitis C patients

Authors: Firdous A. Siddiqui, Murray N. Ehrinpreis, James Janisse, Ravi Dhar, Elizabeth May, Milton G. Mutchnick

Published in: Hepatology International | Issue 3/2008

Login to get access

Abstract

Purpose

Recent studies suggest that African Americans (AA) with chronic hepatitis C (CHC) differ from non-Hispanic whites (NHW) with respect to the natural history and mortality resulting from the complications of chronic liver disease. The aim of this study was to examine the demographics of a large cohort of CHC patients and identify potential differences between AA and NHW.

Methods

This is a retrospective analysis, consisting of 2,739 hepatitis C antibody-positive patients seen at Wayne State University between 1995 and 2005. Patient demographics, risk factors, comorbidities, alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum hepatitis C (HCV) RNA levels, genotype, and liver biopsy results were recorded.

Results

AA constituted 75.4%, NHW 22.5%, and Asians or Hispanics 2.1% of the patients. Males predominated (58%), and the mean age of AA and NHW was 50.0 and 45.3 years, respectively (P ≤ 0.001). The most common risk factor was injection drug use in 55.3% (AA 57.1% vs. NHW 49.7%; P ≤ 0.002). HCV RNA by PCR obtained in 2,407 patients was positive in 94.8%, with a high viral load in 61%. Genotype 1 was significantly more frequent in AA (92.6%) than in NHW (70.6%, P ≤ 0.001). AA had lower median ALT levels (P ≤ 0.001). In those patients who were biopsied, there was no significant difference in fibrosis between the two groups. Aspartate to platelet index calculated in those patients who were not biopsied showed significantly lower fibrosis scores in AA.

Conclusions

In this large cohort of CHC patients from a single institution, AA were older at presentation, had a higher prevalence of genotype 1, but significantly lower ALT levels than NHW.
Literature
1.
go back to reference Edlin BR. Five million Americans infected with the Hepatitis C virus: a corrected estimate. Hepatology 2005;42(4, Suppl 1):44 Edlin BR. Five million Americans infected with the Hepatitis C virus: a corrected estimate. Hepatology 2005;42(4, Suppl 1):44
2.
go back to reference Alter MJ, Jruzon-Moran MS, Nanina O, Mcquillan GM, Gao F, Margolis H, et al. The prevalence of hepatitis C infection in the United States, 1988 through 1994. New Engl J Med 1999;341:556–562PubMedCrossRef Alter MJ, Jruzon-Moran MS, Nanina O, Mcquillan GM, Gao F, Margolis H, et al. The prevalence of hepatitis C infection in the United States, 1988 through 1994. New Engl J Med 1999;341:556–562PubMedCrossRef
4.
go back to reference Wiley TE, Brown J, Chan J. Hepatitis C infection in African-Americans: its natural history and histological progression. Am J Gastroenterol 2002;97:700–706PubMedCrossRef Wiley TE, Brown J, Chan J. Hepatitis C infection in African-Americans: its natural history and histological progression. Am J Gastroenterol 2002;97:700–706PubMedCrossRef
5.
go back to reference Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004;117:163–168PubMedCrossRef Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004;117:163–168PubMedCrossRef
6.
go back to reference Samuel D. Chronic hepatitis C treatment patterns in African-Americans: an update. Am J Gastroenterol 2005;100:716–722CrossRef Samuel D. Chronic hepatitis C treatment patterns in African-Americans: an update. Am J Gastroenterol 2005;100:716–722CrossRef
7.
go back to reference Muir AJ, Bornstein JD, Killenberg PG. Atlantic coast hepatitis treatment group. Peginterferon alfa–2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350(22):2265–2271PubMedCrossRef Muir AJ, Bornstein JD, Killenberg PG. Atlantic coast hepatitis treatment group. Peginterferon alfa–2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350(22):2265–2271PubMedCrossRef
8.
go back to reference Kinzie JL, Naylor PH, Nathani MG, Peleman RR, Ehrinpreis MN, Lybik M, et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat 2001;8:264–269PubMedCrossRef Kinzie JL, Naylor PH, Nathani MG, Peleman RR, Ehrinpreis MN, Lybik M, et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat 2001;8:264–269PubMedCrossRef
9.
go back to reference Khan A, Mutchnick M, Ehrinpreis M, Dhar R, Siddiqui F. African-Americans with genotype-1 with chronic hepatitis C respond poorly to pegylated-interferon and ribavirin combination treatment as compared to Caucasians. Am J Gastroenterol 2005;100(Suppl):311 Khan A, Mutchnick M, Ehrinpreis M, Dhar R, Siddiqui F. African-Americans with genotype-1 with chronic hepatitis C respond poorly to pegylated-interferon and ribavirin combination treatment as compared to Caucasians. Am J Gastroenterol 2005;100(Suppl):311
10.
go back to reference Conjeevaram HS, Fried MW, Jeffers LJ, Terralt N, Wiley-Lucas TE, Afdal N, et al. Peg-interferon alfa-2a and ribavirin in African-American and Caucasian patients with chronic hepatitis C, genotype 1. Gastroenterology 2006;131(2):470–477PubMedCrossRef Conjeevaram HS, Fried MW, Jeffers LJ, Terralt N, Wiley-Lucas TE, Afdal N, et al. Peg-interferon alfa-2a and ribavirin in African-American and Caucasian patients with chronic hepatitis C, genotype 1. Gastroenterology 2006;131(2):470–477PubMedCrossRef
11.
go back to reference Nguyen HA, Miller AI, Dieperink E, Willenbring ML, Tetrick LL, Durfee JM, et al. Spectrum of disease in U.S. veteran patients with hepatitis C. Am J Gastroenterol 2002;97:1813–1820PubMedCrossRef Nguyen HA, Miller AI, Dieperink E, Willenbring ML, Tetrick LL, Durfee JM, et al. Spectrum of disease in U.S. veteran patients with hepatitis C. Am J Gastroenterol 2002;97:1813–1820PubMedCrossRef
12.
go back to reference Cheung RC, Currie S, Shen H, Ho SB, Bini EJ, Wright TL, et al. VA HCV-001 Study Group. Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 2005;100:2186–2193 Cheung RC, Currie S, Shen H, Ho SB, Bini EJ, Wright TL, et al. VA HCV-001 Study Group. Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 2005;100:2186–2193
13.
go back to reference Celona AF, Yu MC, Prakash M, Kuo T, Bonacini M. Hepatitis C in a Los Angeles public hepatitis clinic: demographic and biochemical differences associated with race-ethnicity. Clin Gastroenterol Hepatol 2004;2:459–462PubMedCrossRef Celona AF, Yu MC, Prakash M, Kuo T, Bonacini M. Hepatitis C in a Los Angeles public hepatitis clinic: demographic and biochemical differences associated with race-ethnicity. Clin Gastroenterol Hepatol 2004;2:459–462PubMedCrossRef
14.
go back to reference Howell C, Jeffers L, Hoofnagle J. Hepatitis C in African-Americans: summary of a workshop. Gastroenterology 2000;119:1385–1396PubMedCrossRef Howell C, Jeffers L, Hoofnagle J. Hepatitis C in African-Americans: summary of a workshop. Gastroenterology 2000;119:1385–1396PubMedCrossRef
15.
go back to reference Crosse K, Onuora GU, Anania F, Laurin J, Papadimitriou J, Drachenberg C, et al. Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clinical Gastroenterol Hepatol 2004;2:463–468CrossRef Crosse K, Onuora GU, Anania F, Laurin J, Papadimitriou J, Drachenberg C, et al. Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clinical Gastroenterol Hepatol 2004;2:463–468CrossRef
16.
go back to reference Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ, Contos MJ, Mills AS, et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004;2:469–473PubMedCrossRef Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ, Contos MJ, Mills AS, et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004;2:469–473PubMedCrossRef
17.
18.
go back to reference Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al. Racial differences in response to therapy with Interferon in CHC. Hepatology 1999;30:787–793PubMedCrossRef Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al. Racial differences in response to therapy with Interferon in CHC. Hepatology 1999;30:787–793PubMedCrossRef
19.
go back to reference Fleckenstein J. Chronic hepatitis C in African Americans and other minority groups. Curr Gastroenterol Rep 2004;6(1):66–70PubMedCrossRef Fleckenstein J. Chronic hepatitis C in African Americans and other minority groups. Curr Gastroenterol Rep 2004;6(1):66–70PubMedCrossRef
20.
go back to reference Bedossa P, Poynard T, for the French METAVIR Cooperative Study Group. An algorithm for grading activity in chronic hepatitis C. Hepatology 1996;24:2889–2893 Bedossa P, Poynard T, for the French METAVIR Cooperative Study Group. An algorithm for grading activity in chronic hepatitis C. Hepatology 1996;24:2889–2893
21.
go back to reference Man RE, Smart RG, Auglin L, Adlef EM. Reduction in cirrhosis deaths in the US: association with per capita consumption and AA membership. J Study Alcohol 1991;52:361–365 Man RE, Smart RG, Auglin L, Adlef EM. Reduction in cirrhosis deaths in the US: association with per capita consumption and AA membership. J Study Alcohol 1991;52:361–365
23.
go back to reference Nyugen MH, Whittemore AS, Garcia RT, Tawfeek SA, Ning J, Lam S, et al. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol 2004;2:820–824CrossRef Nyugen MH, Whittemore AS, Garcia RT, Tawfeek SA, Ning J, Lam S, et al. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol 2004;2:820–824CrossRef
24.
go back to reference El-Serag HB. Hepatocellular carcinoma. Recent trends in United States. Gastroenterology 2004;127:S27–S34PubMedCrossRef El-Serag HB. Hepatocellular carcinoma. Recent trends in United States. Gastroenterology 2004;127:S27–S34PubMedCrossRef
25.
go back to reference Siddiqui F, Mutchnick M, Kinzie J, Peleman R, Naylor P, Ehrinpreis M. Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. Am J Gastroenterol 2001;96:858–863PubMedCrossRef Siddiqui F, Mutchnick M, Kinzie J, Peleman R, Naylor P, Ehrinpreis M. Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. Am J Gastroenterol 2001;96:858–863PubMedCrossRef
26.
go back to reference Buffington J, Damon S, Moyer L, Culver D. CDC, Atlanta, GA. Racial differences in the knowledge regarding hepatitis C virus infection. JAMA 2000;284:1651–1652PubMedCrossRef Buffington J, Damon S, Moyer L, Culver D. CDC, Atlanta, GA. Racial differences in the knowledge regarding hepatitis C virus infection. JAMA 2000;284:1651–1652PubMedCrossRef
27.
go back to reference McHutchinson JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, et al. The impact of interferon plus ribavirin on response to treatment in black patients with chronic hepatitis C. Gastroenterology 2000;119:1317–1323 McHutchinson JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, et al. The impact of interferon plus ribavirin on response to treatment in black patients with chronic hepatitis C. Gastroenterology 2000;119:1317–1323
28.
go back to reference Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa–2a (40 kD) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004;39:1702–1708PubMedCrossRef Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa–2a (40 kD) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004;39:1702–1708PubMedCrossRef
29.
go back to reference Gish RG, Afdhal NH, Dieterich DT, Reddy KR. Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol 2005;3:311–318PubMedCrossRef Gish RG, Afdhal NH, Dieterich DT, Reddy KR. Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol 2005;3:311–318PubMedCrossRef
30.
go back to reference Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham N, Sterling RK, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008;47:789–798PubMedCrossRef Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham N, Sterling RK, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008;47:789–798PubMedCrossRef
31.
go back to reference Snyder N, Gajula L, Xiao SY, Grady J, Luxon, Lau DT, et al. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol 2006;40(6):535–542 Snyder N, Gajula L, Xiao SY, Grady J, Luxon, Lau DT, et al. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol 2006;40(6):535–542
32.
go back to reference Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase to platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007;46(3):912–921PubMedCrossRef Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase to platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007;46(3):912–921PubMedCrossRef
Metadata
Title
Demographics of a large cohort of urban chronic hepatitis C patients
Authors
Firdous A. Siddiqui
Murray N. Ehrinpreis
James Janisse
Ravi Dhar
Elizabeth May
Milton G. Mutchnick
Publication date
01-09-2008
Publisher
Springer-Verlag
Published in
Hepatology International / Issue 3/2008
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-008-9086-x

Other articles of this Issue 3/2008

Hepatology International 3/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine